Literature DB >> 25654671

Impact of toll-like-receptor-9 (TLR9) deficiency on visceral adipose tissue adipokine expression during chronic DSS-induced colitis in mice.

T Karrasch1, A Schmid1, A Kopp2, F Obermeier2, C Hofmann2, A Schäffler1.   

Abstract

BACKGROUND: Studies postulate an involvement of adipokines in inflammatory gastrointestinal diseases. Leptin-deficient ob/ob mice as well as TLR9-deficient mice have a more moderate course of chronic DSS-induced colitis (DSS-CC) and adipocytes do express functional TLR9 molecules.
MATERIAL AND METHODS: Adipokine mRNA expression in visceral adipose tissue of mice before and after the induction of DSS-CC was investigated. Experiments were performed in both TLR9(wt/wt) and TLR9(-/-) mice. In vitro, the effect of TLR9 blocking peptide on leptin and visfatin protein secretion was studied in 3T3-L1 adipocytes.
RESULTS: Induction of DSS-CC led to an upregulation of leptin mRNA expression in TLR9(wt/wt) mice, while TLR9(-/-) animals showed a significant reduction of leptin expression even below baseline. While visfatin expression remained unchanged in TLR9(wt/wt) animals, TLR9(-/-) mice exhibited a significant induction during DSS-CC. CTRP-3 expression was reduced after colitis induction only in TLR9(-/-) animals. Of note, IL-6 expression levels remained unchanged, while CXCL1/KC and cyclophilin A expression was reduced in DSS-CC. Inhibition of TLR9 signaling by using TLR9 blocking peptide led to reduced leptin protein secretion into cell culture supernatants in 3T3-L1 adipocytes, while visfatin protein secretion was enhanced.
CONCLUSIONS: DSS-CC leads to differential adipokine expression profiles in the visceral fat pad in TLR9(wt/wt) vs. TLR9(-/-) mice. In vitro, inhibition of TLR9 signaling induces visfatin secretion while inhibiting leptin secretion in adipocytes. Thus, visceral adipokines are regulated by intact TLR9 signaling pathway and a specific interplay between the leptin- and the TLR9-pathways might be of pathophysiological importance in chronic intestinal inflammation. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25654671     DOI: 10.1055/s-0034-1398502

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  5 in total

Review 1.  [The effect of obesity on disease activity of inflammatory rheumatic diseases].

Authors:  Ulf Müller-Ladner; Klaus Frommer; Thomas Karrasch; Elena Neumann; Andreas Schäffler
Journal:  Z Rheumatol       Date:  2021-03-27       Impact factor: 1.372

2.  Hyaluronidase inhibits reactive adipogenesis and inflammation of colon and skin.

Authors:  Tatsuya Dokoshi; Ling-Juan Zhang; Teruaki Nakatsuji; Christopher A Adase; James A Sanford; Rudolph D Paladini; Hiroki Tanaka; Mikihiro Fujiya; Richard L Gallo
Journal:  JCI Insight       Date:  2018-11-02

Review 3.  Adipokines and the role of visceral adipose tissue in inflammatory bowel disease.

Authors:  Thomas Karrasch; Andreas Schaeffler
Journal:  Ann Gastroenterol       Date:  2016-09-06

4.  Regulation of CAMP (cathelicidin antimicrobial peptide) expression in adipocytes by TLR 2 and 4.

Authors:  Alexandra Höpfinger; Thomas Karrasch; Andreas Schäffler; Andreas Schmid
Journal:  Innate Immun       Date:  2021-01-28       Impact factor: 2.680

Review 5.  Adipokines and Their Role in Intestinal Inflammation.

Authors:  Carl Weidinger; Jörn F Ziegler; Marilena Letizia; Franziska Schmidt; Britta Siegmund
Journal:  Front Immunol       Date:  2018-10-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.